<DOC>
	<DOCNO>NCT01839630</DOCNO>
	<brief_summary>This study obtain characteristic treatment pattern unresectable HCC patient candidate systemic therapy decision treat sorafenib early stage TACE treatment course ( concomitantly use later 3rd TACE procedure ) make real-life practice conditions.this study also conclude safety effectiveness combination uHCC patient .</brief_summary>
	<brief_title>Sorafenib Concomitantly Used With TACE ( Transarterial Chemoembolization ) uHCC ( Unresectable Hepatocellular Carcinoma ) Patients China</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically/ cytologically document radiographically diagnose unresectable HCC candidate systemic therapy decision treat sorafenib make . Radiographic diagnosis need typical finding HCC radiographic method i.e . multidimensional dynamic CT , CT hepatic arteriography ( CTHA ) /CT arterial portography ( CTAP ) MRI ; Patients receive first dose sorafenib later 1 week ( &lt; =7days ) 3rd TACE procedure Patients receive prior systemic treatment use target therapy Patients must sign informed consent form ; Patients must life expectancy least 3 month ; The physician must willing complete submit CRFs ; The physician must willing submit site audit verification source document validation data report ; The first dose sorafenib 7 day 3nd TACE procedure Exclusion criterion must follow approve local product information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>TACE combination</keyword>
	<keyword>Treatment pattern</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
</DOC>